Latest Daily News

Latest News
February 13, 2017

Experts review the current research and questions regarding the optimal perioperative strategy for the treatment of renal cell carcinoma.

Read more
February 7, 2017

The Genitourinary Cancers Symposium Clinical Corner allows expert physicians to answer questions posed by an attendee during previous Best of ASCO Meetings. 

Read more
February 9, 2017

At the present time, genetic evaluation guidelines for prostate cancer primarily focus on BRCA1 and BRCA2 testing. The overall risk of prostate cancer has been reported up to 3.8-fold for men who carry BRCA1 mutations and up to 8.6-fold for men who carry BRCA2 mutations.

Read more

February 9, 2017

The United States and United Kingdom treat prostate cancer differently when it comes to active surveillance. Read why.

Read more

February 9, 2017

Dr. Neha Vapiwala discusses the role of whole-body MRI in prostate cancer staging.

Read more

February 9, 2017

In urothelial carcinoma, is there a difference in efficacy or safety among agents that target PD-1 vs. agents that target PD-L1? 

Read more

February 9, 2017

In bladder cancer, what do you recommend for second-line treatment once disease progresses after combination gemcitabine/cisplatin?

Read more

February 9, 2017

Dr. Neha Vapiwala highlights the findings from the ProtecT trial, which compared surgery, radiation, and active surveillance for the treatment of localized prostate cancer.

Read more
February 9, 2017

Experts discuss the current imaging techniques for staging and managing muscle-invasive and metastatic bladder cancer, as well as other promising imaging options currently being studied. 

Read more
February 9, 2017

Dr. Jeanny B. Aragon-Ching discusses the pros and cons of new treatments for patients with oligometastatic prostate cancer.

Read more
February 9, 2017

Active surveillance has emerged as a therapeutic strategy for small renal masses in patients for whom the risks of surgical treatment may outweigh the oncologic benefits of resection.

Read more
February 9, 2017

Experts discuss the complex relationship between androgen signaling and hypoxia-driven signaling pathways in prostate cancer and how to tailor chemotherapy, radiotherapy, and immunotherapy to treat this disease.

Read more

February 9, 2017

Pulitzer Prize-nominated journalist Howard Wolinsky discusses his personal experience with active surveillance for prostate cancer.

Read more

February 9, 2017

Dr. Ashish M. Kamat (pictured) and Dr. Matthew T. Campbell discuss the state of immunotherapeutics and targeted therapy and the potential impact of biomarkers and molecular subtyping in personalizing therapy for urothelial cancer.

Read more
February 9, 2017

Patients with non–clear cell RCC represent a heterogeneous group of distinct disease entities. These patients have historically been underrepresented in clinical trials, and there is a need for further prospective studies exploring current and novel agents in this patient population. 

Read more
January 9, 2016

Prof. David Dearnaley answers a question posed by an attendee during a 2015 Best of ASCO® meeting.

Read more

January 9, 2016

Drs. John Christodouleas, Jason Efstathiou, and Libni Eapen discuss the recent advances in adjuvant radiation for the treatment of locally advanced bladder cancer and NRG Oncology’s NRG-GU001 clinical trial.

Read more

January 9, 2016

Drs. Toni K. Choueiri and Rana R. McKay discuss the ongoing studies exploring novel agents and combinations that will likely inform the future treatment landscape of patients with mRCC.

Read more
January 9, 2016

Dr. Katherine M. Krajewski, a presenter in the Best of Journals: Renal Cell Cancer session, summarizes recent advances in RCC imaging and the role of imaging in patient care.

Read more
January 9, 2015

Dr. Gabriel G. Malouf and coauthors compare Cavafy’s road to “Ithaca” with the journey to discovering new therapies for genitourinary cancers.

Read more